208 related articles for article (PubMed ID: 18006778)
21. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
[TBL] [Abstract][Full Text] [Related]
22. Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene.
Vandier D; Rixe O; Brenner M; Gouyette A; Besnard F
Cancer Res; 1998 Oct; 58(20):4577-80. PubMed ID: 9788604
[TBL] [Abstract][Full Text] [Related]
23. Absence of in vitro or in vivo bystander effects in a thymidine kinase-transduced murine T lymphoma.
Rivas C; Chandler P; Melo JV; Simpson E; Apperley JF
Cancer Gene Ther; 2000 Jun; 7(6):954-62. PubMed ID: 10880028
[TBL] [Abstract][Full Text] [Related]
24. A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation.
Samoto K; Perng GC; Ehtesham M; Liu Y; Wechsler SL; Nesburn AB; Black KL; Yu JS
Cancer Gene Ther; 2001 Apr; 8(4):269-77. PubMed ID: 11393279
[TBL] [Abstract][Full Text] [Related]
25. Transduction of glioma cells using a high-titer retroviral vector system and their subsequent migration in brain tumors.
Tamura M; Ikenaka K; Tamura K; Yoshimatsu T; Miyao Y; Kishima H; Mabuchi E; Shimizu K
Gene Ther; 1998 Dec; 5(12):1698-704. PubMed ID: 10023449
[TBL] [Abstract][Full Text] [Related]
26. Long-term rat survival after malignant brain tumor regression by retroviral gene therapy.
Izquierdo M; Cortés M; de Felipe P; Martín V; Díez-Guerra J; Talavera A; Perez-Higueras A
Gene Ther; 1995 Jan; 2(1):66-9. PubMed ID: 7712334
[TBL] [Abstract][Full Text] [Related]
27. [Gene transduction for experimental brain tumors using recombinant adenovirus vector].
Ichikawa T; Tamiya T; Adachi Y; Ono Y; Matsumoto K; Furuta T; Ohmoto T; Yoshida Y; Hamada H
No To Shinkei; 1998 Aug; 50(8):731-8. PubMed ID: 9757466
[TBL] [Abstract][Full Text] [Related]
28. Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: consequences for anti-cancer gene therapy.
Hoshi M; Harada A; Kawase T; Uyemura K; Yazaki T
Cancer Gene Ther; 2000 May; 7(5):799-805. PubMed ID: 10830727
[TBL] [Abstract][Full Text] [Related]
29. Quantitation of HSV mass distribution in a rodent brain tumor model.
Schellingerhout D; Rainov NG; Breakefield XO; Weissleder R
Gene Ther; 2000 Oct; 7(19):1648-55. PubMed ID: 11083473
[TBL] [Abstract][Full Text] [Related]
30. Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector.
Dupont F; Avalosse B; Karim A; Mine N; Bosseler M; Maron A; Van den Broeke AV; Ghanem GE; Burny A; Zeicher M
Gene Ther; 2000 May; 7(9):790-6. PubMed ID: 10822306
[TBL] [Abstract][Full Text] [Related]
31. Inflammatory thoughts about glioma gene therapy.
Kielian T; Hickey WF
Nat Med; 1999 Nov; 5(11):1237-8. PubMed ID: 10545984
[TBL] [Abstract][Full Text] [Related]
32. Intraarterial delivery of genetic vectors for the treatment of malignant brain tumors.
Cohen ZR; Duvdevani R; Nass D; Hadani M; Ram Z
Isr Med Assoc J; 2001 Feb; 3(2):117-20. PubMed ID: 11344821
[TBL] [Abstract][Full Text] [Related]
33. Treatment of glioblastoma by direct inoculation of concentrated high titer-recombinant retrovirus carrying the herpes simplex virus thymidine kinase gene.
Ikenaka K; Sasaki M; Tamura K; Tamura M; Miyao Y; Nanmoku K; Kawano Y; Nakahira K; Yoshimine T; Shimizu K
Hum Cell; 2001 Mar; 14(1):49-58. PubMed ID: 11436353
[TBL] [Abstract][Full Text] [Related]
34. [Gene therapy for cerebral tumors: use of an adenovirus in the glioma C6 rat model].
Maron A
Bull Mem Acad R Med Belg; 1999; 154(6 Pt 2):377-80. PubMed ID: 10992887
[TBL] [Abstract][Full Text] [Related]
35. Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene.
Benedetti S; Bruzzone MG; Pollo B; DiMeco F; Magrassi L; Pirola B; Cirenei N; Colombo MP; Finocchiaro G
Cancer Res; 1999 Feb; 59(3):645-52. PubMed ID: 9973213
[TBL] [Abstract][Full Text] [Related]
36. Quantitative 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: identification of apoptotic response.
Hakumäki JM; Poptani H; Puumalainen AM; Loimas S; Paljärvi LA; Ylä-Herttuala S; Kauppinen RA
Cancer Res; 1998 Sep; 58(17):3791-9. PubMed ID: 9731486
[TBL] [Abstract][Full Text] [Related]
37. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
Galanis E; Bateman A; Johnson K; Diaz RM; James CD; Vile R; Russell SJ
Hum Gene Ther; 2001 May; 12(7):811-21. PubMed ID: 11339897
[TBL] [Abstract][Full Text] [Related]
38. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector.
Herrlinger U; Kramm CM; Aboody-Guterman KS; Silver JS; Ikeda K; Johnston KM; Pechan PA; Barth RF; Finkelstein D; Chiocca EA; Louis DN; Breakefield XO
Gene Ther; 1998 Jun; 5(6):809-19. PubMed ID: 9747461
[TBL] [Abstract][Full Text] [Related]
39. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene.
Kim JH; Kim SH; Brown SL; Freytag SO
Cancer Res; 1994 Dec; 54(23):6053-6. PubMed ID: 7954444
[TBL] [Abstract][Full Text] [Related]
40. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum.
DePolo NJ; Reed JD; Sheridan PL; Townsend K; Sauter SL; Jolly DJ; Dubensky TW
Mol Ther; 2000 Sep; 2(3):218-22. PubMed ID: 10985952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
